SARS-CoV-2 NSP14 inhibitor exhibits potent antiviral activity and reverses NSP14-driven host modulation
8.5
来源：
Nature
关键字：
medical imaging+deep learning
发布时间：
2025-11-03 23:44
摘要：
C10 is identified as a potent and selective inhibitor of SARS-CoV-2 NSP14, demonstrating significant antiviral activity against SARS-CoV-2 and its variants. The compound exhibits a unique mechanism of action by targeting the SAM-binding pocket of NSP14, leading to suppression of viral translation and modulation of host responses. In vivo studies in transgenic mouse models confirm its efficacy, positioning C10 as a promising candidate for further development in antiviral therapies against COVID-19.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0分+生物技术领域符合度
business_impact
0.8分+获得投资
scientific_rigor
1.5分+具体实验数据支撑
timeliness_innovation
1.5分+重大创新
investment_perspective
2.5分+早期研发阶段
market_value_relevance
1.0分+高发疾病相关性
team_institution_background
0.5分+知名机构背景
technical_barrier_competition
1.0分+技术壁垒高
关键证据
C10 demonstrates robust antiviral activity against SARS-CoV-2, with EC50 values comparable to remdesivir.
The study highlights a novel mechanism of NSP14 in SARS-CoV-2 pathogenesis and its therapeutic potential.
C10's efficacy was validated in a transgenic mouse model of SARS-CoV-2 infection.
真实性检查
否
AI评分总结
C10 is identified as a potent and selective inhibitor of SARS-CoV-2 NSP14, demonstrating significant antiviral activity against SARS-CoV-2 and its variants. The compound exhibits a unique mechanism of action by targeting the SAM-binding pocket of NSP14, leading to suppression of viral translation and modulation of host responses. In vivo studies in transgenic mouse models confirm its efficacy, positioning C10 as a promising candidate for further development in antiviral therapies against COVID-19.